Failure to Satisfy Listing Rule (Form 8-K)

On April 21, 2025, Invivyd, Inc. (the "Company") received a deficiency letter (the "Letter")from the Nasdaq Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for a period of 30 consecutive business days, the bid price for the Company's common stock, $0.0001 par value per share (the "Common Stock"), had closed below the$1.00 per share minimumrequired for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"). The Letterhas no immediate effect on the listing of the Common Stock, which continues to trade on The Nasdaq Global Market under the symbol "IVVD" at this time.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has until October 20, 2025 to regain compliance with the Minimum Bid Price Requirement (the "Initial Compliance Period"). To regain compliance, the closing bid price for the Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days during the Initial Compliance Period, unless the Staff exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H).

If the Company does not regain compliance with the Minimum Bid Price Requirement by October 20, 2025, the Company may be eligible for an additional 180 calendar day period to regain compliance (the "Second Compliance Period"). To qualifyfor the Second Compliance Period, the Company would be required to transfer to The Nasdaq Capital Market (the "Capital Market") and meet the continued listing requirement for market value of publicly held shares on the Capital Market and all other applicable requirements for initial listing on the Capital Market, except for the Capital Market's bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the Second Compliance Period. As part of its review processto determine whether the Second Compliance Periodwould be granted to the Company, the Staff would make a determination about whether it believes the Company will be able to cure the deficiency. If the Staff concludes that the Company will not be able to cure the deficiency, or if the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by the Staff, the Staff will provide written notice to the Company that the Common Stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearings Panel (a "Panel"). However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by the Staff to a Panel, such appeal would be successful.

The Company intends to actively monitor the closing bid price for the Common Stock and, as appropriate, will consider implementing available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement.